Show simple item record

dc.contributor.authorMolina Martín, Juan de Dios
dc.contributor.authorÁvila, Sonia
dc.contributor.authorRubio, Gabriel
dc.contributor.authorLópez Muñoz, Francisco
dc.date.accessioned2022-08-03T08:38:37Z
dc.date.available2022-08-03T08:38:37Z
dc.date.issued2022
dc.identifier.issn1381-6128spa
dc.identifier.urihttp://hdl.handle.net/10641/3080
dc.description.abstractBackground: Diagnosis of schizophrenia lacks of reliable medical diagnostic tests and robust biomarkers applied to clinical practice. Schizophrenic patients undergoing treatment with SGAs suffer a reduced life expectancy due to metabolic disarrangements that co-exist with their own mental illness and predispose them to develop metabolic syndrome, also exacerbated by antipsychotic treatment. Metabolomics is an emerging and potent technology able to accelerate this biomedical research. Aim: This review focus on a detailed vision of the molecular mechanisms involved both in schizophrenia and antipsychotic-induced metabolic syndrome, based on innovative metabolites that consistently change in nascent metabolic syndrome, drug-naïve, first episode psychosis and/or schizophrenic patients compared to healthy subjects. Main lines: Supported by metabolomic approaches, although not exclusively, noteworthy variations are reported mainly through serum samples of patients and controls in several scenes: 1) alterations in fatty acids, inflammatory response indicators, amino acids and biogenic amines, biometals and gut microbiota metabolites (schizophrenia); 2) alterations in metabolites involved in carbohydrate and gut microbiota metabolism, inflammation and oxidative stress (metabolic syndrome), some of them shared with the schizophrenia scene (e.g., uric acid); 3) alterations of cytokines secreted by adipose tissue, phosphatidylcholines, acylcarnitines, Sirtuin 1, orexin-A and changes in microbiota composition (antipsychotic-induced metabolic syndrome). Conclusion: Novel insights into the pathogenesis of schizophrenia and the metabolic side-effects associated to its antipsychotic-treatment, represent an urgent request for scientifics and clinicians. Considering the biological environment that covers mental illness is a challenge needy of cutting-edge technologies such as metabolomics to strengthen solid biomarkers and preventive, diagnostic and therapeutical solutions.spa
dc.language.isoengspa
dc.publisherCurrent Pharmaceutical Designspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectSchizophreniaspa
dc.subjectMetabolic syndromespa
dc.subjectMetabolomicsspa
dc.subjectSecond-generation antipsychoticsspa
dc.subjectBiomarkerspa
dc.subjectGut microbiotaspa
dc.subjectDiagnosisspa
dc.titleMetabolomic Connections between Schizophrenia, Antipsychotic Drugs and Metabolic Syndrome: A Variety of Players.spa
dc.typejournal articlespa
dc.type.hasVersionSMURspa
dc.rights.accessRightsopen accessspa
dc.description.extent232 KBspa
dc.identifier.doi10.2174/1381612827666210804110139spa
dc.relation.publisherversionhttps://www.eurekaselect.com/article/117021spa


Files in this item

FilesSizeFormatView
5.- Metabolomic connections ...231.6KbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España